Clinical Trials Logo
  1. Home
  2. Bipolar I Disorder
  3. NCT00046384
  4. Details
NCT00046384 Clinical Trial

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder

Bipolar I Disorder Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00046384
Other study ID # CN138-077
Secondary ID
Status Completed
Phase Phase 3
First received September 27, 2002
Last updated November 7, 2013
Start date June 2002
Est. completion date April 2003

Study information
Verified date September 2007
Source Otsuka Pharmaceutical Development & Commercialization, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to learn if aripiprazole is effective in the treatment of patients with acute symptoms of Bipolar Disorder.

Recruitment information / eligibility
Status Completed
Enrollment 0
Est. completion date April 2003
Est. primary completion date April 2003
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Patients with acute symptoms of Bipolar Disorder

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• aripiprazole

Locations
Country Name City State
Argentina Local Institution Mendoza
United States Local Institution Bellevue Washington
United States Local Institution Chula Vista California
United States Local Institution Falls Church Virginia
United States Local Institution Little Rock Arkansas
United States Local Institution Nashville Tennessee
United States Local Institution Oklahoma City Oklahoma
United States Local Institution Pico Rivera California
United States Local Institution Riverside California
United States Local Institution San Diego California
United States Local Institution Scottsdale Arizona
United States Local Institution Staten Island New York
United States Local Institution Washington District of Columbia
United States Local Institution Winter Park Florida

Sponsors (1)
Lead Sponsor Collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc.

Countries where clinical trial is conducted

United States,  Argentina, 

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Withdrawn NCT01495156 - Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania Phase 4
Completed NCT00982020 - Study in Adolescents With Schizophrenia or Bipolar Disorder Phase 4
Completed NCT00746343 - Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study N/A
Completed NCT00177463 - L-Carnosine for Bipolar I Disorder N/A
Completed NCT03257865 - A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder Phase 3
Completed NCT03259555 - A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder Phase 3
Not yet recruiting NCT06433635 - Sequential Multiple Assignment Randomized Trial for Bipolar Depression Phase 4
Completed NCT04127058 - Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia Phase 1
Recruiting NCT05977023 - NMDA Receptor Modulation for the Treatment of Bipolar I Disorder Phase 2
Recruiting NCT05340686 - Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression N/A
Completed NCT03287869 - A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder. Phase 3
Enrolling by invitation NCT04987229 - Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects Phase 3
Completed NCT00761761 - Sensoril(Ashwaganhda)for Bipolar Disorder Phase 3
Completed NCT00232414 - A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder Phase 3
Completed NCT03292848 - Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders Phase 1
Active, not recruiting NCT04561622 - Emotional Proactive Processing in Bipolar Disorder
Recruiting NCT03943537 - Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders Phase 2
Completed NCT03334721 - Gabapentin for Bipolar & Cannabis Use Disorders Phase 2
Active, not recruiting NCT05658510 - Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) Phase 3

External Links